^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Sitoiganap (ERC1671)

    i
    Other names: ERC1671, ERC-1671, ERC 1671
    Company:
    Epitopoietic Research Corp
    Drug class:
    Immunostimulant
    Related drugs:
    7ms
    Glioblastoma Cell Lysate and Adjuvant Nanovaccines via Strategic Vaccination Completely Regress Established Murine Tumors. (PubMed, Adv Healthc Mater)
    In an orthotopic hRas-GBM model induced by a lentiviral plasmid, GlioVac resulted in ≈100% complete tumor regression. These findings suggest that GlioVac provides a personalized therapeutic vaccine strategy for glioblastoma.
    Preclinical • Journal
    |
    HRAS (Harvey rat sarcoma viral oncogene homolog) • CD8 (cluster of differentiation 8)
    |
    Sitoiganap (ERC1671)
    9ms
    ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme (clinicaltrials.gov)
    P2, N=84, Active, not recruiting, Epitopoietic Research Corporation | Trial completion date: Mar 2023 --> Jun 2026 | Trial primary completion date: Mar 2023 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule) • CSF2 (Colony stimulating factor 2)
    |
    Avastin (bevacizumab) • cyclophosphamide • Sitoiganap (ERC1671) • Leukine (sargramostim)
    over3years
    A Prospective, Cohort Study of SITOIGANAP to Treat Glioblastoma When Given in Combination With Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Nivolumab or Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Pembrolizumab in Patients Who Failed Prior Treatment With Surgical Resection, Radiation, and Temozolomide. (PubMed, Front Oncol)
    The enrollment and end-of-study CD3/CD4 T-lymphocyte counts strongly correlate with OS. The addition of SITOIGANAP/GM-CSF/cyclophosphamide to bevacizumab and an anti-PD-1 monoclonal antibody resulted in a significant survival benefit compared to historic control values in rGBM with minimal toxicity compared to current therapy.
    Journal • Combination therapy
    |
    CD4 (CD4 Molecule) • CSF2 (Colony stimulating factor 2)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • temozolomide • cyclophosphamide • Sitoiganap (ERC1671)
    over3years
    ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab (clinicaltrials.gov)
    P2, N=28, Not yet recruiting, Epitopoietic Research Corporation
    New P2 trial • Combination therapy
    |
    CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • temozolomide • cyclophosphamide • Sitoiganap (ERC1671)
    over4years
    ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme (clinicaltrials.gov)
    P2, N=84, Active, not recruiting, University of California, Irvine | Recruiting --> Active, not recruiting
    Clinical • Enrollment closed
    |
    IL6 (Interleukin 6) • IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule) • IL10 (Interleukin 10) • CSF2 (Colony stimulating factor 2)
    |
    Avastin (bevacizumab) • cyclophosphamide • Sitoiganap (ERC1671) • Leukine (sargramostim) • cyclophosphamide intravenous